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Intranasal oxytocin enhances intrinsic corticostriatal
functional connectivity in women
RAI Bethlehem1,13, MV Lombardo1,2,13, M-C Lai1,3,4, B Auyeung1,5, SK Crockford1, J Deakin6,7, S Soubramanian6,8, A Sule6, P Kundu9,10,
V Voon6,7,8,11 and S Baron-Cohen1,12
Oxytocin may inﬂuence various human behaviors and the connectivity across subcortical and cortical networks. Previous oxytocin
studies are male biased and often constrained by task-based inferences. Here, we investigate the impact of oxytocin on resting-
state connectivity between subcortical and cortical networks in women. We collected resting-state functional magnetic resonance
imaging (fMRI) data on 26 typically developing women 40 min following intranasal oxytocin administration using a double-blind
placebo-controlled crossover design. Independent components analysis (ICA) was applied to examine connectivity between
networks. An independent analysis of oxytocin receptor (OXTR) gene expression in human subcortical and cortical areas was carried
out to determine plausibility of direct oxytocin effects on OXTR. In women, OXTR was highly expressed in striatal and other
subcortical regions, but showed modest expression in cortical areas. Oxytocin increased connectivity between corticostriatal
circuitry typically involved in reward, emotion, social communication, language and pain processing. This effect was 1.39 standard
deviations above the null effect of no difference between oxytocin and placebo. This oxytocin-related effect on corticostriatal
connectivity covaried with autistic traits, such that oxytocin-related increase in connectivity was stronger in individuals with higher
autistic traits. In sum, oxytocin strengthened corticostriatal connectivity in women, particularly with cortical networks that are
involved in social-communicative, motivational and affective processes. This effect may be important for future work on
neurological and psychiatric conditions (for example, autism), particularly through highlighting how oxytocin may operate
differently for subsets of individuals.
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INTRODUCTION
Oxytocin is a neuropeptide hormone involved in sexual inter-
course, childbirth and parent–infant bonding, affecting reward
processing, anxiety and social salience.1 Oxytocin is not necessa-
rily a ‘pro-social’ hormone, as effects are highly context- and
person-dependent.1,2 Oxytocin has received substantial interest as
a potential treatment for psychiatric conditions such as autism
spectrum conditions (ASC; henceforth autism),3 although clinical
trials show modest effects.4–6 Given the marked heterogeneity in
autism,7 it is possible that the beneﬁts of oxytocin may vary
substantially between individuals. For example, on average
intranasal oxytocin improves eye contact during naturalistic social
interaction, but the largest effects occur for individuals who
typically make the least amount of eye contact.8 Thus, in evaluat-
ing oxytocin’s therapeutic potential, we must move towards a
more precise understanding of how its effects may vary across
individuals.
We have theorized that the widespread effects of oxytocin on
complex human social behavior may be due to distributed
inﬂuence at a neural circuit level.9 Although oxytocin acts directly
at a local level via the oxytocin receptor (OXTR), it can potentially
affect widespread circuit-level dynamics via connections to areas
that are densely populated with OXTR. One way to test the
hypothesis that oxytocin affects circuit-level organization in the
human brain is through oxytocin-administration studies within the
context of in-vivo measurement of intrinsic functional brain
organization (that is, connectome or brain network organization)
with resting-state functional magnetic resonance imaging (rsfMRI)
data. Although there are a number of existing neuroimaging
oxytocin-administration studies,9 most have relied on task-based
fMRI paradigms and largely focus on males. In the oxytocin
literature there is a prominent bias towards males, and one
that affects much of neuroscience and medical research.10 Sex
differences in the OXTR system are documented,11–13 suggesting
that ﬁndings in males may not generalize to females. Furthermore,
task-based fMRI has often shown opposite ﬁndings in males and
females namely in terms of amygdala activation.14,15 Because
oxytocin is viewed as a potential pharmacotherapy for conditions
like autism, and given that sex may have a large moderating roles
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in drug effectiveness,16 it is essential to begin examining how
oxytocin operates in the female brain. In addition, although
there is a strong male bias in autism diagnoses,17 there is reason
to believe that females are strongly underrepresented that
may have increased the male-biased understanding of autism.18
Given the lack of prior literature on oxytocin’s network level
effects on brain connectivity in women we chose to use a
robust data-driven (hypothesis-free) approach to assess potential
connectivity differences.
The majority of studies investigating how oxytocin affects the
human brain use task-based fMRI paradigms. Although task-based
studies are important for targeting speciﬁc psychological pro-
cesses, examination of oxytocin-related effects may, as a result, be
neuroanatomically constrained to speciﬁc circuits related to those
tasks. Examination of functional connectivity using rsfMRI data
allows for task-independent assessment of oxytocin’s effect on
intrinsic functional brain organization across the entire connec-
tome. Furthermore, the small number of existing rsfMRI oxytocin-
administration studies5,13,19,20 use seed-based analyses that do not
allow for hypothesis-free examination across the connectome.
Thus, a more unconstrained approach could provide novel
insights into oxytocin-related effects on connectome organization,
especially when little to no prior hypothesis can be derived from
existing literature.
Here, we use independent components analysis (ICA) to
examine how connectivity between-circuits (that is, between-
component connectivity)21,22 differs across oxytocin and placebo.
To facilitate our understanding of oxytocin effects on connectivity
in the human brain, we analyzed two publicly available post-
mortem human brain gene-expression data sets to answer the
question of how the oxytocin receptor (OXTR) is expressed across
a variety of subcortical and cortical areas in the human brain. To
date, information on OXTR expression has largely been conﬁned
to animal studies and translation from that is problematic.23 We
predicted that oxytocin would have largest impact on connectivity
between the densely OXTR-populated striatum and cortical circuits.
Furthermore, we predicted that impact of oxytocin on connectiv-
ity would vary as a function of variation in autistic traits, with
larger effects for individuals with higher levels of autistic traits.8
MATERIALS AND METHODS
Participants
All research was conducted in accordance with the Declaration of Helsinki
and the study had received ethical approval from the NHS Research Ethics
Service (NRES Committee East of England—Cambridge Central; REC
reference number 14/EE/0202). This study was exempt from clinical trials
status by the UK Medicines and Healthcare Regulatory Agency (MHRA).
In a double-blind randomized placebo-controlled crossover design, 26
women (age: 23.6 ± 4.6 years, range (21–50)) received an oxytocin nasal
spray (24 IU, 40.32 μg, Syntocinon-spray; Novartis, Switzerland, pump-
actuated) in one session and placebo (the same solution except for the
active oxytocin) in the other session in a counterbalanced order. After
instruction by a trained medical doctor the sprays were self-administered
40 min prior24 to undergoing resting-state fMRI imaging. Participants
conﬁrmed no nasal congestion or obstruction on the day of testing. This
timing and dosage are by far the most commonly used in oxytocin
administration studies to date.25 Sessions were separated by at least
1 week (to ensure full wash-out from the ﬁrst administration) when
participants were on hormonal contraceptive (19/26). When participants
were not on hormonal contraceptive (7/26) both sessions took place in the
early follicular phase of the menstrual cycle to ensure similar hormone
levels between sessions. Exclusion criteria included pregnancy, smoking, a
diagnosis of bipolar, obsessive-compulsive, panic or psychotic disorder, use
of any psychoactive medication within 1 year prior to the study, substance
dependence, epilepsy and being post-menopausal. These criteria were
assessed by self-report and participants’ general practitioners were given
the full protocol prior to participation and asked to notify the research
term if they thought there was any reason for exclusion. More details on
the testing procedure and sample are provided in the Supplementary
Information and Supplementary Table S1. Brieﬂy, all subject completed the
Wechsler Abbreviated Scale of Intelligence26 (mean 115.3 ± 13.19),
empathy quotient27 (mean 55.6 ± 14.53)) and autism quotient28 (mean
14.4 ± 7.32) questionnaires prior to the ﬁrst scanning session. None of the
participants had received a formal diagnosis of autism nor did they give
any indication that they may have gone undiagnosed. Although we
acknowledge no assessment was done to formally rule this out. They were
instructed to refrain from alcohol or caffeine on the day of testing and
from food and drink 2 h prior to testing (except for water).
To understand whether oxytocin or some other placebo-related effect
that explains any drug-related differences in connectivity, we utilized an
independent data set of age-matched typical females to ascertain what are
the normative baseline between-component connectivity effects. Our logic
here is that if normative connectivity looks similar to patterns we see
during placebo, then we can reasonably infer that oxytocin is the primary
reason for the induced change in connectivity and not due to some
placebo-related change and no effect of oxytocin. This independent data
set consisted of 50 females whom were slightly older but did not
statistically differ in age (mean age 31.6 ± 12.2, Wilcoxon rank-sum test:
W= 764.5, P= 0.117) collected on the same scanner and which used a
similar multi-echo echo planar imaging (EPI) sequence for data collection
(see Morris et al., 29 for full details).
Image acquisition and pre-processing
MRI scanning was done on a 3T Siemens MAGNETOM Tim Trio MRI scanner
at the Wolfson Brain Imaging Centre in Cambridge, UK. For the oxytocin-
data set, a total of 270 resting-state functional volumes (eyes-open, with
ﬁxation cross) were acquired with a multi-echo EPI30 sequence with online
reconstruction (repetition time (TR), 2300 ms; ﬁeld-of-view (FOV), 240 mm;
33 oblique slices, alternating slice acquisition, slice thickness 3.8 mm, 11%
slice gap; 3 echoes at TE = 12, 29 and 46 ms, GRAPPA acceleration factor 2,
BW=2368 Hz pixel− 1, ﬂip angle 80°). Anatomical images were acquired
using a T1-weighted magnetization prepared rapid gradient echo
(MPRAGE) sequence (TR 2250 ms; TI 900 ms; TE 2.98 ms; ﬂip angle 9°;
matrix 256× 256× 256, FOV 256 mm). For the independent rsfMRI data set
on age-matched females, data was acquired on the same 3 T scanner and
with a multi-echo EPI sequence that was similar to the oxytocin-data set
(TR 2470 ms; FOV 240 mm; 32 oblique slices, alternating slice acquisition,
slice thickness 3.75 mm, 10% slice gap; 4 echoes at TE = 12, 28, 44 and
60 ms, GRAPPA acceleration factor 3, BW=1698 Hz/pixel, ﬂip angle 78°).
Multi-echo functional images were pre-processed and denoised using the
AFNI integrated multi-echo independent component analysis (ME-ICA,
meica.py v3, beta1; http://afni.nimh.nih.gov) pipeline,31 details on this
procedure are outlines in the Supplementary Information.
Gene-expression analysis
To better characterize subcortical and cortical brain regions in terms of
OXTR gene expression, we analyzed RNAseq data in the Allen Institute
BrainSpan atlas (http://www.brainspan.org) and the Genotype-Tissue
Expression (GTEx) consortium data set (http://www.gtexportal.org/home/
). The BrainSpan atlas covers a number of cortical areas the might provide
insights into potential cortical targets of oxytocin expression, whereas the
GTEx data set does not have many regionally speciﬁc areas of the cortex
(only BA9 and BA24) and mostly includes more detailed information on
several subcortical brain regions. In these analyses we used all postnatal
(birth to 79 years) samples in each data set, stratiﬁed by biological sex.
OXTR was isolated and plots were produced to descriptively indicate
expression levels across brain regions. Expression levels in both data sets
were summarized as reads per kilobase of transcript per million mapped
reads. Full details for the BrainSpan and GTEx procedures are available in
their white papers; http://bit.ly/2dqRF47 and http://bit.ly/2e8o1W2, respec-
tively. To examine whether OXTR expression levels were signiﬁcantly
elevated in each brain region, we compared expression levels against zero
and, as a more conservative test, against another tissue from GTEx, where
we would not expect OXTR to be expressed (that is, skin). These tests were
carried out using permutation t-tests (1000 permutations) implemented
with the perm.t.test function in R.
Group ICA and dual regression
To assess large-scale intrinsic functional organization of the brain, we ﬁrst
utilized the unsupervised data-driven method of ICA to conduct a group-
ICA followed by a dual regression to back-project spatial maps and
individual time series for each component and subject. Both group-ICA
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and dual regression were implemented with FSL’s MELODIC and Dual
Regression tools (www.fmrib.ox.ac.uk/fsl). For group-ICA, we constrained
the dimensionality estimate to 30, as in most cases with low-dimensional
ICA, the number of meaningful components can be anywhere from 10 to
30.21 Some components were localized primarily to white matter and
although likely may be driven by true BOLD-related signal (due to high ME-
ICA kappa weighting), were not considered in any further analyses. Overall,
22 out of 30 components were manually classiﬁed as primarily localized to
gray matter and were clearly not noise-driven components. Correlation
matrices were constructed for all component pairs, these were assessed for
signiﬁcance using paired sampled t-tests and resulting P-values were
corrected for multiple comparison using Bonferroni correction at a family-
wise error rate of 5%. Difference scores were computed for pairs that
survived family-wise error correction on the Fisher z-transformed correlation
scores32 and entered into robust regression (for insensitivity to outliers)33
with AQ scores. For more details see the Supplementary Information.
Large-scale reverse inference with cognitive decoding in
NeuroSynth
To better characterize the components showing an oxytocin-related effect
on connectivity we used the decoder function in NeuroSynth34 to compare
the whole-brain component maps with large-scale automated meta-
analysis maps within NeuroSynth. The top 100 terms (excluding terms for
brain regions) ranked by the correlation strength between the component
map and the meta-analytic map were visualized as a word cloud using the
wordcloud library in R, with the size of the font scaled by correlation
strength.
RESULTS
OXTR gene expression in the female human brain
Expression proﬁles of OXTR in women derived from the GTEx data
set reveal broad expression across subcortical regions, but with
notable enrichments particularly in nucleus accumbens, substantia
nigra and the hypothalamus (Figure 1). All regions showed OXTR
expression that was signiﬁcantly above 0 and critically was also
signiﬁcantly stronger than expression in a tissue we would expect
to show little expression (that is, skin) (Supplementary Table S2).
Cortical regions from the BrainSpan data set also exhibit
signiﬁcant OXTR expression (above 0 and when compared to
skin; Supplementary Table S2), albeit at much more modest levels
than some subcortical regions. This modest degree of OXTR
expression may be particularly relevant given studies that show
broad oxytocin-related effects on complex human social behavior,
social communication and social cognition that affects distributed
cortical regions (for example, superior temporal gyrus, medial
prefrontal cortex). However, there is a lack of speciﬁcity apparent
in OXTR expression in cortex, as most regions show similar levels
of expression. As a whole, these data indicate that oxytocin could
have potent direct effects on OXTR within subcortical circuitry,
particular areas of the striatum and midbrain, but may also have
similar OXTR-driven effects to a lesser extent across most cortical
areas where OXTR expression is modest. Given the lack of
speciﬁcity within cortex, these data also support an approach
for examining oxytocin-related effects on intrinsic functional
connectivity that examines all between-networks connections, as
all may be susceptible to plausible effects. However, given the
enrichment particularly in striatal and midbrain regions, it is likely
that oxytocin-related effects on connectivity may particularly
affect connections between cortex and the densely OXTR-
populated striatum and midbrain. We also carried out exploratory
analyses on gender differences in OXTR expression and these
are included in Supplementary Information and Supplementary
Figure S1.
Oxytocin-related between-component connectivity differences
Analyses of all pairwise comparisons of between-component
connectivity differences as a function of oxytocin administration
revealed only one pair of components, IC11 and IC21 (Figures 2a
and b), whose connectivity was substantially affected by oxytocin
(t(24) = 6.99, P= 3.10e− 7, effect size d= 1.39, 95% CI (0.96–1.86))
and survived after Bonferroni correction (family-wise error
Figure 1. Oxytocin receptor (OXTR) gene expression in the female human brain. This ﬁgure illustrates OXTR gene expression measured via
RNAseq in BrainSpan (http://www.brainspan.org) and GTEx (http://www.gtexportal.org/home/) data sets. (a) Expression for all subcortical
regions available in the GTEx data set in women. All brain regions show signiﬁcant expression of OXTR above 0 and compared to expression in
non-brain (skin) tissue. On-average, OXTR expression is particularly enriched in ventral striatum (nucleus accumbens), substantia nigra and
hypothalamus. (b) Expression for all cortical areas and the thalamus available in the BrainSpan atlas in women. All areas also show signiﬁcant,
albeit modest, levels of OXTR expression compared to 0 and non-brain (skin) tissue.
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Po0.05) for multiple comparisons. The full pairwise-correlation
matrix is provided in Supplementary Figure 2. As shown in
Figure 2e, all but 2 participants (92%; 23/25) showed evidence of a
non-zero oxytocin-related boost in connectivity over the placebo
condition (Figure 2e). Within the placebo condition alone,
connectivity was not different from 0 (t(24) =− 0.86, P= 0.39).
However, within the oxytocin condition, connectivity was
substantially elevated above 0 (t(24) = 6.22, P= 1.95e− 6).
The IC11 component comprised regions in primary auditory
cortex, middle and posterior divisions of the insula, superior
temporal gyrus, posterior superior temporal sulcus, middle and
posterior cingulate cortex, ventromedial prefrontal cortex,
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amygdala and superior parietal lobe. These brain regions overlap
with areas typically considered important in processes such as
language, social communication, self-referential and social cogni-
tion, pain and emotion.35–39 NeuroSynth decoding revealed that
most of the terms with the highest correlation with IC11 were
predominantly terms referring to pain-related, motor-related or
language/speech-related processes (Figure 2c). The IC21 compo-
nent was comprised entirely of subcortical regions such as the
striatum, basal ganglia, amygdala, thalamus, midbrain and
brainstem. These regions, particularly the striatum, midbrain and
amygdala, are typically considered highly involved in reward and
emotion-related processes.40–42 This was again conﬁrmed with
NeuroSynth decoding showing a predominance of reward,
motivation and affective terms (Figure 2d).
Next, we examined whether individual differences in autistic
traits accounted for variability in oxytocin-related effects on
connectivity between these networks in an exploratory analysis.
Given prior work suggesting that oxytocin may have its largest
effect on individuals who show the most atypical social behavior,8
we hypothesized that oxytocin may have the largest effects on
connectivity in individuals with the highest degree of autistic
traits. Here, we found evidence conﬁrming this hypothesis, as
oxytocin’s effect on between-component connectivity appeared
to increase with increased degree of autistic traits: r= 0.41, one-
tailed P= 0.0351 (Figure 2f).
Finally, we ran further analyses to aid the interpretation of such
an effect. One interpretation could be that oxytocin is the primary
driver of enhanced connectivity between these components.
However, the alternative could be that oxytocin has no effect on
connectivity, and that the placebo might somehow induce a
decrease in connectivity between these components. To tease
apart these different interpretations, we looked to an independent
data set of rsfMRI to ascertain what the normative connectivity
strength is between these two components. If oxytocin was truly
enhancing connectivity between these components, we would
predict that connectivity between these components under
normative conditions would be similar to those seen under
placebo. That is, normative connectivity effects between these
components should manifest similarly to placebo and on average
show no difference from 0. We identiﬁed two components that
spatially appeared nearly identical to the component pair we
observed an oxytocin effect in; nIC4 and nIC21 (Figures 2i and j).
Quantitatively conﬁrming this similarity, we ﬁnd very large
correlations between the spatial component maps of the
normative and oxytocin/placebo data sets (nIC4-IC11, r= 0.80;
nIC21-IC21, r= 0.69, Figure 2h). No other components showed
anywhere near such strong correlations (all ro0.2). Similar to our
placebo condition, this component pair showed connectivity that
was not signiﬁcantly different from zero: t(49) = 1.23, P= 0.22
(Figure 2g). Furthermore, comparison between normative con-
nectivity and connectivity during placebo revealed no statistical
difference (t-test with unequal variance assumed and degrees of
freedom estimated using Satterthwaite’s approximation; t(64.6) =
− 1.507, P= 0.1370). This further clariﬁes our interpretation that it is
indeed the oxytocin condition that drives enhancements in
connectivity between these components and that the placebo
condition is a good approximation of normative functional
connectivity effects within this corticostriatal circuit.
DISCUSSION
To our knowledge, this is the ﬁrst study to investigate how
oxytocin affects intrinsic functional organization of the human
brain at the level of between-network interactions. We discovered
a speciﬁc corticostriatal network implicated in social-communica-
tive, motivational and affective processes that is heavily affected
by oxytocin. Under oxytocin, the connectivity between these two
components was substantially elevated on average and an
oxytocin-related boost was observed in almost all participants.
The fact that these corticostriatal connections are not particularly
strong under normative conditions and with the administration of
placebo, but become increasingly coordinated under oxytocin
may be important for understanding how oxytocin inﬂuences
cognition and behavior. Future work is needed to examine
oxytocin-related strengthening of connectivity between these
circuits and its effect on speciﬁc cognitive and behavioral
processes. For example, these corticostriatal connections under
pain or social-communication processes may illuminate important
brain-behavior links that are affected by oxytocin. These results
also illustrate how oxytocin is likely to extend beyond certain brain
regions traditionally thought to be important.43 For example,
previous neuroimaging studies in humans have largely focused on
amygdala-related effects and to a lesser extent on striatal regions.
The current study suggests oxytocin’s effects may extend well
beyond the amygdala and striatum, and most importantly, may
incorporate interactions between subcortical striatal regions with
cortical areas.
The degree to which oxytocin enhanced connectivity was also
associated with continuous variation in autistic traits, such that
those with the highest levels of autistic traits showed the largest
oxytocin-related effect on connectivity. These results may point
towards the idea that oxytocin may have varying impact on
different subsets of individuals. Individuals with the highest levels
of autistic traits seem to show the largest oxytocin-related
connectivity boost. It will be important to extend these ideas into
neuropsychiatric conditions such as ASC. Oxytocin is hypothesized
to be of some potential value therapeutically for autism.43
However, given the large degree of heterogeneity in ASC7 and
the knowledge that therapies may work well for some individuals
and not others, it will be of the utmost importance to examine
how oxytocin may or may not work well on speciﬁc subsets of
affected individuals.
Supporting the plausibility of oxytocin-related effects on
connectivity between these circuits, we also showed evidence
supporting the idea that many of the brain regions involved in
both IC11 and IC21 maps show some degree of OXTR expression.
For instance, it is well known from non-human animal work that
the striatum and regions within the midbrain are highly populated
with oxytocin receptors.44,45 Here, we conﬁrmed such ﬁnding with
evidence from OXTR expression in the brain in human females and
Figure 2. Oxytocin-related enhancement of intrinsic functional connectivity. (a) The spatial map of component IC11. Voxels are colored by Z-
statistics indicating how well each voxel’s time series ﬁts the component’s time series. (b) The same information for component IC21. (c) The
top 100 terms associated with component IC11 based on NeuroSynth decoding and font size represents relative correlation strength of that
term to the component. (d) The same information for component IC21. (e) Connectivity between IC11 and IC21 for each subject during
placebo or oxytocin administration. Dots represent individual subjects and the lines connect each individual’s data under placebo and
oxytocin, with the positive slopes indicating an enhancement of connectivity after oxytocin administration. Underneath the individual-level
data are boxplots that indicate the median, interquartile range and outer fences. Interestingly, the two individuals who would be considered
outliers in the placebo condition are the minority of individuals showing no enhancement of connectivity as a function of oxytocin. (f) The
relationship between oxytocin-related effects on connectivity and continuous variation in autistic traits as measured by the AQ. (g) The
between-component connectivity of between comparable components of the normative data set. (h) The spatial correlation between the
oxytocin data components and the two normative components that were selected. (i, j) The normative components spatial maps.
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furthered a proof-of-concept evidence that oxytocin may leverage
this enrichment in OXTR to inﬂuence neural circuits connected to
the striatum. We also discovered that there are modest levels of
OXTR expression throughout many cortical areas. Given the lack of
cortical speciﬁcity for OXTR enrichment, it remains possible that
the observed connectivity effects with rsfMRI may not necessarily
be mediated by direct action of oxytocin on OXTR in speciﬁc
cortical regions. Rather, oxytocin could exert such effects via other
indirect routes, perhaps originating in striatal circuitry where there
is highly enrichment in OXTR or via other mechanisms of action.9
Although expression patterns of OXTR were not speciﬁc to cortical
regions it may be that more ﬁne-grained spatial maps of OXTR
might provide a clearer picture. For example, the development of
a PET ligand could certainly further advance our understanding of
OXTR distribution in-vivo in the human brain.
This study has several novel elements that need to be
highlighted. Speciﬁcally, this study focusses speciﬁcally on
oxytocin-related resting-state effects in women. There are notable
male biases throughout neuroscience and medical research and
this bias may explain why studies looking at the effects of drugs
tend to miss many adverse effects or show a lack of efﬁcacy when
applied to females.10,46 This bias can be observed in much of the
prior work on oxytocin in humans as well, with some neuroima-
ging studies indicating potential differences in the oxytocin
system between sexes.13,14,47–49 Part of this bias in oxytocin
research might be explained by the higher risk of side-effects (for
example, lactation in mothers, abnormal uterine contractions and
elevated blood pressure), though the intranasal administration has
proven to be a safe methods of administration.25 There have been
a few studies that assessed the effect of gender in oxytocin
administration. For example, previous studies examining func-
tional connectivity during tasks show enhanced connectivity in
women but decreased connectivity in men.47,50 Although our
study was not explicitly set to examine sex differences in the
effects of oxytocin, future research should focus on how oxytocin
may have different effects across males and females.
Second, surpassing much of the existing neuroimaging work on
oxytocin, to our knowledge, our study is the ﬁrst to take a whole-
brain, unsupervised approach to examine connectivity between
neural networks. The small number of studies examining in-vivo
oxytocin-related changes to functional connectivity in humans
utilized a seed-based connectivity approach. This approach
elucidates effects of oxytocin on connectivity with the pre-
selected seed region, but is limited by the a priori selection. As we
have shown with the analysis of OXTR expression much of the
prior work is not necessarily informed by this expression pattern. It
partly lacks speciﬁcity for certain regions and the present data
suggest that other brain regions, not traditionally reported in
oxytocin administration literature, might also have OXTR expres-
sion that would make it a potential target for administration.
Rather, prior work tends to be heavily directed to regions that are
justiﬁed based on their role in psychological processes that are
linked to oxytocin (for example, amygdala). In our work, we have
taken an unbiased approach to provide insight into oxytocin’s
effect on corticostriatal connectivity. These circuits might not have
been identiﬁed with an approach constrained by task-based
activation or seed-based connectivity based on this task-related
activation.
The highlighted effect places emphasis on striatal interactions
with cortical areas that are associated with pain processing. These
results are interesting in light of work showing that oxytocin can
not only act as an anxiolytic,51,52 but can also act as a painkiller.53
It should be noted that the anxiolytic effect might not fully explain
oxytocins effect on behavior as benzodiazepines do not show a
similar behavioral effect. To our knowledge, there is little
neuroimaging work in females focusing on oxytocin and its
inﬂuence on neural systems for pain processing, as most
published work is exclusively on males and/or is focused on
empathy for pain.54–57 Similar to oxytocin research, research on
pain has traditionally been heavily male biased,16 whereas women
tend to suffer more from acute and chronic pain.58 Our results
suggest that future work is needed in this area, particularly on
oxytocin’s effect on pain and how such corticostriatal networks
may be involved. In addition, areas identiﬁed by this data-driven
approach show that key areas in the brains reward circuitry are
modulated by oxytocin administration. It has been previously
hypothesized that oxytocin exerts its effect on social salience and
social cognition by modulating stress and reward processing.1 The
present study also highlights neural systems underlying these
cognitive processes as key target for oxytocin administration.
Further research into how oxytocin speciﬁcally modulates social
reward processing might shed further light on its potential to
more broadly modulate social cognition.
There are some caveats and limitations to keep in mind. First,
the sample size is moderate and potentially provides low power to
detect small effects. However, our multi-echo fMRI approach is a
strength that could help counteract issues associated with
statistical power. Multi-echo EPI acquisition and the ME-ICA
denoising technique employed here is known to greatly enhance
temporal signal-to-noise ratio and allow for enhanced ability to
reduce false positives.31 These enhancements tied to principled
elimination of non-BOLD noise in rsfMRI could be beneﬁcial for
power because reduction in noise potentially increases observable
effect sizes,59 and reduce effect size estimates for false-positive
effects. Future work collecting larger samples to replicate and
extend these ﬁndings would be facilitated by characterizing
individuals in continuous variation in autistic traits. Our study
indicates that oxytocin-related effects tend to be stronger in
individuals with more autistic traits. As noted in the points about
sex and gender, future work should also examine whether similar
or different effects are present in males. It would also be important
to further extend this work in clinically diagnosed individuals with
autism. Our exploratory analysis revealed a potential correlation
with autistic traits that may suggest that oxytocin could facilitate
corticostriatal connectivity in clinically diagnosed patients. If such
a relationship extends into the clinically diagnosed population of
the autism spectrum, we may expect to see that oxytocin provides
the largest enhancements to the most affected individuals.8 This
should however at this point be considered exploratory.
Furthermore, there has been some debate in recent years about
the extend to which oxytocin crosses the blood–brain barrier.60 A
recent study that assessed cerebrospinal ﬂuid and plasma
concentrations after intranasal administration found elevated
levels in plasma after 15 min and a peak in cerebrospinal ﬂuid
elevation at 75 min.61 By far, most studies have used the 24 IU
dose and timing of 40 min to show behavioral effects.9,25,43 Yet, is
is possible some behavioral effects might originate from
peripheral elevation as opposed to a central effect.60 Nonetheless,
a recent review on the issue suggest that the intranasal route is
likely still the best candidate for administration and found no
effects from intravenous administration.62 The relation between
increased cerebrospinal ﬂuid oxytocin and timing of potential
behavioral effect also remains unclear. The present study was not
set out to determine the best dose or timing or to assess whether
oxytocin could cross the blood–brain barrier. Unfortunately, there
is currently no PET ligand available to deﬁnitively assess the timing
and central binding of intranasal oxytocin, though animal work on
this is progressing.63,64 Thus, to be able to compare the present
ﬁndings to existing literature, we chose to use the same timing
and dosage.
Finally, underpowered studies are common amongst oxytocin
administration studies.65 The observed effect here between IC11
and IC21 is large. For the current sample size, the minimum effect
size achieving 80% power at an alpha of 0.05 is d= 0.6. An effect
this low or lower was never observed in our bootstrapping
analysis to estimate variability in the IC11-IC21 effect
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(Supplementary Figure 3). Therefore, we can reason that we had
sufﬁcient power to detect such an effect at the current sample
size. As for other more subtle effects, our report here is likely
underpowered to detect such effects and much larger studies are
likely needed to detect such smaller effects. To our knowledge,
this is the ﬁrst work on the topic of between-component
connectivity in a female rsfMRI oxytocin administration study,
we have provided effect sizes estimates for all IC comparisons to
aid others in future power calculations (Supplementary Figure 4).
Each of the corresponding 22 IC maps can be viewed and
downloaded on NeuroVault (http://neurovault.org/collections/
2154/).
In conclusion, we have discovered that oxytocin enhances
corticostriatal connectivity in women. These corticostriatal net-
works have roles in social-communicative, motivational and
affective processes, and the results may be particularly important
for understanding how oxytocin changes neurodynamics that may
be relevant for many neuropsychiatric conditions with deﬁcits in
those domains and neural circuits. Future work examining these
effects in males as well as clinically diagnosed samples will be
important, as will be the examination of what subsets of
individuals may beneﬁt most from oxytocin-related changes in
between-network connectivity.
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